Search company, investor...

Founded Year

2013

Stage

Unattributed | Alive

Total Raised

$146.34M

Last Raised

$2.74M | 1 yr ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+30 points in the past 30 days

About nference

nference is a science-first software company that focuses on transforming unstructured data from electronic medical records (EMR) into powerful software solutions in the healthcare and life sciences industry. The company's main services include the development of software products that enable the synthesis of biomedical information, the creation of AI-enabled solutions for healthcare, and the provision of tools that unlock insights from structured and unstructured patient records. nference primarily sells to the healthcare ecosystem, with a focus on medical centers and biopharmaceutical companies. It was founded in 2013 and is based in Cambridge, Massachusetts.

Headquarters Location

One Main Street, Suite 400 East Arcade, 4th Floor

Cambridge, Massachusetts, 02142,

United States

Loading...

ESPs containing nference

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare & Life Sciences / Drug R&D Tech

The biomedical natural language processing (NLP) market uses advanced algorithms and linguistic models to extract and analyze information from vast amounts of biomedical text data such as scientific literature, electronic health records, and clinical trial reports. By leveraging biomedical NLP solutions, researchers, clinicians, and pharmaceutical companies can gain actionable insights, discover h…

nference named as Leader among 5 other companies, including Causaly, Huma.AI, and Biorelate.

Loading...

Research containing nference

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned nference in 5 CB Insights research briefs, most recently on Jan 8, 2024.

Expert Collections containing nference

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

nference is included in 5 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

11,617 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.

D

Digital Health 50

150 items

The winners of the second annual CB Insights Digital Health 150.

D

Digital Health

10,804 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

P

Precision Medicine Tech Market Map

160 items

This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.

D

Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

nference Patents

nference has filed 25 patents.

The 3 most popular patent topics include:

  • electronic health records
  • health informatics
  • computational linguistics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/7/2021

2/13/2024

Natural language processing, Computational linguistics, Knowledge representation, Data management, Semantic Web

Grant

Application Date

7/7/2021

Grant Date

2/13/2024

Title

Related Topics

Natural language processing, Computational linguistics, Knowledge representation, Data management, Semantic Web

Status

Grant

Latest nference News

nference Signs Multi-Year Licensing Deal With The Bill & Melinda Gates Foundation

Feb 7, 2024

nference (a company dedicated to transforming healthcare by making biomedical data computable) announced a multi-year licensing agreement with the Bill & Melinda Gates Foundation. This collaboration provides the Gates Foundation access to nference’s nSights platform, where researchers can access a repository of extensive clinical data and expertise from top-ranked medical institutions. nSights’ platform – utilizing nference’s federated network – will provide resources to help the Gates Foundation more easily visualize and investigate pressing issues affecting world health today. and Tthe platform offers data-driven insights to help research teams learn more about healthcare, diseases, and treatments relevant to the Foundation’s interests. This knowledge will contribute to informed decision-making and the development of impactful treatments. nference’ extensive de-identified, longitudinal data includes decades of clinical notes along with rich patient histories, vitals, lab tests, radiology images, digital pathology, genomics, and electrophysiology waveforms. And the company’s federated data platform, comprised of premier healthcare organizations, including Mayo Clinic, Duke Health, Banner Health, Vanderbilt University Medical Center, and Emory Healthcare, enables advanced research and custom AI model development. Through unprecedented access to data from over 40 million patient journeys, the company’s partners can accelerate target discovery, optimize clinical trial design, and enhance lifecycle management. KEY QUOTE: “At the heart of this collaboration lies our commitment to supporting humanitarian causes with our cutting-edge technology platform, driving near-term tangible impact in health equity. Through access to nference’s federated AI – with its depth of multimodal and unprecedented longitudinal data – we aim to accelerate the contribution of modern and innovative healthcare solutions on a global scale.” Maulik Nanavaty, President of Ventures at nference & CEO at Anumana Pulse 2.0 focuses on business news, profiles, and deal flow coverage.

nference Frequently Asked Questions (FAQ)

  • When was nference founded?

    nference was founded in 2013.

  • Where is nference's headquarters?

    nference's headquarters is located at One Main Street, Suite 400, Cambridge.

  • What is nference's latest funding round?

    nference's latest funding round is Unattributed.

  • How much did nference raise?

    nference raised a total of $146.34M.

  • Who are the investors of nference?

    Investors of nference include Matrix Partners, Mayo Clinic Ventures, NTT Venture Capital and Matrix Capital Management.

  • Who are nference's competitors?

    Competitors of nference include Pentavere Research Group, Causaly, Biorelate, Tempus, Amplion and 7 more.

Loading...

Compare nference to Competitors

Standigm Logo
Standigm

Standigm is an AI-driven drug discovery company operating in the pharmaceutical industry. The company's main services include the use of proprietary AI platforms for novel target identification, lead generation, and the creation of commercially valuable drug pipelines. Standigm primarily sells to the pharmaceutical and healthcare industries. It was founded in 2015 and is based in Seoul, South Korea.

Aitia Logo
Aitia

Aitia is a company focused on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. These Digital Twins are used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.

Aetion Logo
Aetion

Aetion operates as a healthcare analytics company. It provides decision-grade real-world evidence solutions to biopharma companies, payers, and regulatory agencies. It offers a platform that analyzes data from the real world to produce scientifically validated answers on treatments, effectiveness, and value. The company was founded in 2012 and is based in New York, New York.

Atomwise Logo
Atomwise

Atomwise develops machine learning-based discovery engines and uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.

Healx Logo
Healx

Healx provides drug discovery services. The company manufactures drugs using technology to bring treatments for rare diseases to patients. Its platform, Healnet, helps face challenges by analyzing drug and disease data points. The company was founded in 2014 and is based in Cambridge, U.K.

Aria Pharmaceuticals Logo
Aria Pharmaceuticals

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using their proprietary Symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.